CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells (CSCs), announced that it was added to the Russell 2000® index effective at the close of the U.S. markets on March 30, 2012.
